Nanoparticles for thrombolytic therapy in ischemic stroke: a systematic review and meta-analysis of preclinical studies

dc.contributor.affiliationUniversidade de Santiago de Compostela. Centro de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS)
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Química Inorgánica
dc.contributor.authorPrego Domínguez, Jesús
dc.contributor.authorLaso-García, Fernando
dc.contributor.authorPalomar-Alonso, Nuria
dc.contributor.authorPérez Mato, María
dc.contributor.authorLópez Arias, Esteban
dc.contributor.authorDopico López, Antonio
dc.contributor.authorHervella, Pablo
dc.contributor.authorGutiérrez-Fernández, María
dc.contributor.authorAlonso de Leciñana, María
dc.contributor.authorPolo Tobajas, Ester
dc.contributor.authorPelaz García, Beatriz
dc.contributor.authorPino González de la Higuera, Pablo Alfonso del
dc.contributor.authorCampos, Francisco
dc.contributor.authorCorrea Paz, Clara
dc.date.accessioned2025-06-02T07:05:25Z
dc.date.available2025-06-02T07:05:25Z
dc.date.issued2025-02-06
dc.description.abstractRecombinant tissue plasminogen activator (rtPA) remains the standard thrombolytic treatment for ischemic stroke. Different types of nanoparticles have emerged as promising tools to improve the benefits and decrease the drawbacks of this therapy. Among them, cell membrane-derived (CMD) nanomedicines have gained special interest due to their capability to increase the half-life of particles in blood, biocompatibility, and thrombus targeting. In order to update and evaluate the efficacy of these nanosystems, we performed a meta-analysis of the selected in vivo preclinical studies. Methods: Preclinical in vivo studies in ischemic stroke models have been identified through a search in the Pubmed database. We included studies of rtPA-nanoparticles, which assessed infarct volume and/or neurological improvement. Nanosystems were compared with free (non-encapsulated) rtPA treatment. Standardized mean differences were computed and pooled to estimate effect sizes for lesion volumes and neurological scores. Subgroup analyses by the risk of bias, type of nanoparticle, and time of administration were also performed. Results: A total of 18 publications were included in the meta-analysis. This was based on defined search inclusion criteria. Our analysis revealed that rtPA-nanoparticles improved both lesion volume and neurological scores compared with the free rtPA treatment. Moreover, CMD nanomedicines showed better evolution of infarct volume compared to the other nanoparticles. Funnel plots of lesion volume exhibited asymmetry and publication bias. Heterogeneity was generally high, and the funnel plot and Egger test showed some evidence of publication bias that did not achieve statistical significance in the trim-and-fill analysis. Conclusions: rtPA-encapsulating nanosystems were shown to decrease infarct volume and improve neurological scales compared to the standard treatment, and CMD nanomedicines had the greatest beneficial effect.
dc.description.peerreviewedSI
dc.description.sponsorshipThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Instituto de Salud Carlos III_ICIII, grant numbers: ICI19/00032, PI20/01014; and the RICORS-ICTUS network: RD21/0006/0003. Xunta de Galicia, grant number: IN607A2022/02. European Union program FEDER, ISCIII Project (AC20/00031), and Euronanomed III Call (Euronanomed2020_143), and Fundación Mutua Madrileña. CC-P would like to thank Sara Borrell (CD23/00005). All authors have read and agreed to the published version of the manuscript
dc.identifier.citationPrego-Domínguez, J., Laso-García, F., Palomar-Alonso, N., Pérez-Mato, M., López-Arias, E., Dopico-López, A., Hervella, P., Gutiérrez-Fernández, M., De Leciñana, M. A., Polo, E., Pelaz, B., Del Pino, P., Campos, F., Correa-Paz, C. (2025). Nanoparticles for thrombolytic therapy in ischemic stroke: a systematic review and meta-analysis of preclinical studies. "Pharmaceutics", vol. 17
dc.identifier.doi10.3390/pharmaceutics17020208
dc.identifier.essn1999-4923
dc.identifier.urihttps://hdl.handle.net/10347/41930
dc.journal.titlePharmaceutics
dc.language.isoeng
dc.publisherMDPI
dc.relation.publisherversionhttps://doi.org/10.3390/pharmaceutics17020208
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCell membrane-derived nanomedicines
dc.subjectIschemic stroke
dc.subjectMeta-analysis
dc.subjectNanoparticles
dc.subjectrtPA
dc.subjectThrombolysis
dc.subject.classification2303 Química inorgánica
dc.titleNanoparticles for thrombolytic therapy in ischemic stroke: a systematic review and meta-analysis of preclinical studies
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number17
dspace.entity.typePublication
relation.isAuthorOfPublication8b9beb32-7cfc-4c41-871e-f0960dcb60e3
relation.isAuthorOfPublicationae6cfd5f-90ba-47e5-9d34-20c3361b7df3
relation.isAuthorOfPublication29d26acf-e713-4d9b-8cf2-8e9ed521f62b
relation.isAuthorOfPublication.latestForDiscovery8b9beb32-7cfc-4c41-871e-f0960dcb60e3

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2025_pharmaceutics_pelaz_nanoparticles.pdf
Size:
4.08 MB
Format:
Adobe Portable Document Format